PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Sponsor
Swiss Cancer Institute
Study ID
NCT00544219
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
    375 mg/m2 i.v. per cycle
  • cyclophosphamide — DRUG
    750 mg/m2 i.v. per cycle
  • doxorubicin hydrochloride — DRUG
    50 mg/m2 i.v. per cycle
  • prednisone — DRUG
    100 mg/day p.o. per cycle
  • vincristine sulfate — DRUG
    1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
  • positron emission tomography — PROCEDURE
    PET Scan during treatment

Study Details

RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Key Dates

Start date
Sep 30, 2007
Status verified
May 2019
Primary completion
Sep 30, 2012
Completion
Jan 31, 2016

Study Design

Enrollment
156 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: R-Chop 14
    Standard treatment

Primary Outcome Measure

Event-free survival [ Time Frame: at 2 years ]

Related Studies